S&P Futures
6,007.00 +3.25 (+0.05%) Dow Futures
43,920.00 +10.00 (+0.02%) Nasdaq Futures
21,241.75 +17.00 (+0.08%) Russell 2000 Futures
2,397.90 +2.20 (+0.09%) Crude Oil
71.91 -0.45 (-0.62%) Gold
2,699.10 -6.70 (-0.25%)
CytoMed Therapeutics Limited (GDTC)
| Previous Close | 2.3900 |
| Open | 2.2850 |
| Bid | 2.3000 x 100 |
| Ask | 0.0000 x 0 |
| Day's Range | 2.2401 - 2.5900 |
| 52 Week Range | 1.2000 - 5.5000 |
| Volume | |
| Avg. Volume | 12,458 |
| Market Cap | 29.312M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.2200 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Simply Wall St.Discovering Penny Stocks On US Exchanges: 3 Picks Under $100M Market Cap
As major U.S. indexes recently experienced a downturn, with technology stocks leading the decline and Treasury yields reaching a three-month high, investors are increasingly seeking opportunities beyond the usual large-cap stocks. Penny stocks, while an older term, continue to represent smaller or newer companies that may offer both affordability and growth potential for those willing to explore them. In this article, we examine three penny stocks that stand out for their financial strength...
GlobeNewswireCytoMed Therapeutics’ first-in-human Phase I ANGELICA clinical trial using its patented donor allogeneic chimeric antigen receptor T cell (CAR-T cell) against blood and solid tumors received co-funding support from the NMRC Clinical Trial Grant
Completion of cash acquisition of licenced cord blood bank expanding CytoMed’s strategy to cord blood-derived biologics through its subsidiary, LongevityBank Pte LtdSINGAPORE, Oct. 07, 2024 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or the “Company”), a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor blood-derived, cell-based allogeneic therapies for the treatment of various cancers including bloo
